Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways

H. Chusho, Y. Ogawa, N. Tamura, M. Suda, A. Yasoda, T. Miyazawa, I. Kishimoto, Y. Komatsu, Hiroshi Itoh, K. Tanaka, Y. Saito, D. L. Garbers, K. Nakao

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Brain natriuretic peptide (BNP), a hormone produced primarily by the cardiac ventricle, is thought to be involved in a variety of homeostatic processes through its cognate receptor, guanylyl cyclase A (GC-A). We previously created transgenic mice overexpressing BNP under the control of the liver-specific human serum amyloid P component promoter (BNP-transgenic mice) and demonstrated that they exhibit reduced blood pressure and cardiac weight accompanied by an elevation of plasma cGMP concentrations and marked skeletal overgrowth through the activation of endochondral ossification. To address whether BNP exerts its biological effects solely through GC-A, we produced BNP-transgenic mice lacking GC-A (BNP-Tg/GC-A(-/-) mice) and examined their cardiovascular and skeletal phenotypes. The GC-A(-/-) mice are hypertensive with cardiac hypertrophy relative to wild-type littermates, which is not alleviated by overexpression of BNP in BNP-Tg/GC-A(-/-) mice. The BNP-Tg/GC-A(-/-) mice, however, continue to exhibit marked longitudinal growth of vertebrae and long bones comparably to BNP-Tg mice. This study provides genetic evidence that BNP reduces blood pressure and cardiac weight through GC-A, whereas it dramatically alters endochondral ossification in the absence of this receptor. Therefore, the BNP-Tg/GC-A(-/-) mice provide the first experimental model demonstrating that this natriuretic peptide can signal in a tissue-specific manner through a receptor other than GC-A.

Original languageEnglish
Pages (from-to)3807-3813
Number of pages7
JournalEndocrinology
Volume141
Issue number10
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Brain Natriuretic Peptide
Genetic Models
Transgenic Mice
Natriuretic Peptides
Osteogenesis
Serum Amyloid P-Component
Blood Pressure
atrial natriuretic factor receptor A
Weights and Measures
Cardiomegaly
Heart Ventricles
Spine
Theoretical Models

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Chusho, H., Ogawa, Y., Tamura, N., Suda, M., Yasoda, A., Miyazawa, T., ... Nakao, K. (2000). Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. Endocrinology, 141(10), 3807-3813.

Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. / Chusho, H.; Ogawa, Y.; Tamura, N.; Suda, M.; Yasoda, A.; Miyazawa, T.; Kishimoto, I.; Komatsu, Y.; Itoh, Hiroshi; Tanaka, K.; Saito, Y.; Garbers, D. L.; Nakao, K.

In: Endocrinology, Vol. 141, No. 10, 2000, p. 3807-3813.

Research output: Contribution to journalArticle

Chusho, H, Ogawa, Y, Tamura, N, Suda, M, Yasoda, A, Miyazawa, T, Kishimoto, I, Komatsu, Y, Itoh, H, Tanaka, K, Saito, Y, Garbers, DL & Nakao, K 2000, 'Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways', Endocrinology, vol. 141, no. 10, pp. 3807-3813.
Chusho H, Ogawa Y, Tamura N, Suda M, Yasoda A, Miyazawa T et al. Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. Endocrinology. 2000;141(10):3807-3813.
Chusho, H. ; Ogawa, Y. ; Tamura, N. ; Suda, M. ; Yasoda, A. ; Miyazawa, T. ; Kishimoto, I. ; Komatsu, Y. ; Itoh, Hiroshi ; Tanaka, K. ; Saito, Y. ; Garbers, D. L. ; Nakao, K. / Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways. In: Endocrinology. 2000 ; Vol. 141, No. 10. pp. 3807-3813.
@article{f8d55485ad0b4e55aa971f10758420d5,
title = "Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways",
abstract = "Brain natriuretic peptide (BNP), a hormone produced primarily by the cardiac ventricle, is thought to be involved in a variety of homeostatic processes through its cognate receptor, guanylyl cyclase A (GC-A). We previously created transgenic mice overexpressing BNP under the control of the liver-specific human serum amyloid P component promoter (BNP-transgenic mice) and demonstrated that they exhibit reduced blood pressure and cardiac weight accompanied by an elevation of plasma cGMP concentrations and marked skeletal overgrowth through the activation of endochondral ossification. To address whether BNP exerts its biological effects solely through GC-A, we produced BNP-transgenic mice lacking GC-A (BNP-Tg/GC-A(-/-) mice) and examined their cardiovascular and skeletal phenotypes. The GC-A(-/-) mice are hypertensive with cardiac hypertrophy relative to wild-type littermates, which is not alleviated by overexpression of BNP in BNP-Tg/GC-A(-/-) mice. The BNP-Tg/GC-A(-/-) mice, however, continue to exhibit marked longitudinal growth of vertebrae and long bones comparably to BNP-Tg mice. This study provides genetic evidence that BNP reduces blood pressure and cardiac weight through GC-A, whereas it dramatically alters endochondral ossification in the absence of this receptor. Therefore, the BNP-Tg/GC-A(-/-) mice provide the first experimental model demonstrating that this natriuretic peptide can signal in a tissue-specific manner through a receptor other than GC-A.",
author = "H. Chusho and Y. Ogawa and N. Tamura and M. Suda and A. Yasoda and T. Miyazawa and I. Kishimoto and Y. Komatsu and Hiroshi Itoh and K. Tanaka and Y. Saito and Garbers, {D. L.} and K. Nakao",
year = "2000",
language = "English",
volume = "141",
pages = "3807--3813",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways

AU - Chusho, H.

AU - Ogawa, Y.

AU - Tamura, N.

AU - Suda, M.

AU - Yasoda, A.

AU - Miyazawa, T.

AU - Kishimoto, I.

AU - Komatsu, Y.

AU - Itoh, Hiroshi

AU - Tanaka, K.

AU - Saito, Y.

AU - Garbers, D. L.

AU - Nakao, K.

PY - 2000

Y1 - 2000

N2 - Brain natriuretic peptide (BNP), a hormone produced primarily by the cardiac ventricle, is thought to be involved in a variety of homeostatic processes through its cognate receptor, guanylyl cyclase A (GC-A). We previously created transgenic mice overexpressing BNP under the control of the liver-specific human serum amyloid P component promoter (BNP-transgenic mice) and demonstrated that they exhibit reduced blood pressure and cardiac weight accompanied by an elevation of plasma cGMP concentrations and marked skeletal overgrowth through the activation of endochondral ossification. To address whether BNP exerts its biological effects solely through GC-A, we produced BNP-transgenic mice lacking GC-A (BNP-Tg/GC-A(-/-) mice) and examined their cardiovascular and skeletal phenotypes. The GC-A(-/-) mice are hypertensive with cardiac hypertrophy relative to wild-type littermates, which is not alleviated by overexpression of BNP in BNP-Tg/GC-A(-/-) mice. The BNP-Tg/GC-A(-/-) mice, however, continue to exhibit marked longitudinal growth of vertebrae and long bones comparably to BNP-Tg mice. This study provides genetic evidence that BNP reduces blood pressure and cardiac weight through GC-A, whereas it dramatically alters endochondral ossification in the absence of this receptor. Therefore, the BNP-Tg/GC-A(-/-) mice provide the first experimental model demonstrating that this natriuretic peptide can signal in a tissue-specific manner through a receptor other than GC-A.

AB - Brain natriuretic peptide (BNP), a hormone produced primarily by the cardiac ventricle, is thought to be involved in a variety of homeostatic processes through its cognate receptor, guanylyl cyclase A (GC-A). We previously created transgenic mice overexpressing BNP under the control of the liver-specific human serum amyloid P component promoter (BNP-transgenic mice) and demonstrated that they exhibit reduced blood pressure and cardiac weight accompanied by an elevation of plasma cGMP concentrations and marked skeletal overgrowth through the activation of endochondral ossification. To address whether BNP exerts its biological effects solely through GC-A, we produced BNP-transgenic mice lacking GC-A (BNP-Tg/GC-A(-/-) mice) and examined their cardiovascular and skeletal phenotypes. The GC-A(-/-) mice are hypertensive with cardiac hypertrophy relative to wild-type littermates, which is not alleviated by overexpression of BNP in BNP-Tg/GC-A(-/-) mice. The BNP-Tg/GC-A(-/-) mice, however, continue to exhibit marked longitudinal growth of vertebrae and long bones comparably to BNP-Tg mice. This study provides genetic evidence that BNP reduces blood pressure and cardiac weight through GC-A, whereas it dramatically alters endochondral ossification in the absence of this receptor. Therefore, the BNP-Tg/GC-A(-/-) mice provide the first experimental model demonstrating that this natriuretic peptide can signal in a tissue-specific manner through a receptor other than GC-A.

UR - http://www.scopus.com/inward/record.url?scp=0033735524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033735524&partnerID=8YFLogxK

M3 - Article

C2 - 11014237

AN - SCOPUS:0033735524

VL - 141

SP - 3807

EP - 3813

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 10

ER -